A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2004
11/02/2004	US6812326 Tumor necrosis factor receptor-associated factor (traf) protein-interacting hereditary multiple extoses (trex) for use in the diagnosis and treatment of cancer and autoimmune disorders; antitummor agents
11/02/2004	US6812258 Cancer treatment composition and method using natural plant essential oils
11/02/2004	US6812254 Pain reliever and method of use
11/02/2004	US6812230 Pharmaceutical compositions useful in treating progressive renal fibrosis in mammals comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a non-peptide ccr1 receptor antagonist.
11/02/2004	US6812224 Phosphorous organic compounds and their use
11/02/2004	US6812220 Pharmaceutical compositions and methods relating to fucans
11/02/2004	US6812214 Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same
11/02/2004	US6812209 Conjugate consisting of an active substance and a non-exogenous native protein
11/02/2004	US6812206 Contacting body fluid from mammal with antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase (haah) polypeptide under conditions sufficient to form antigen-antibody complex and detecting complex
11/02/2004	US6812025 Detection of preferential enzyme inhibitors; obtain sample containing enzyme, incubate with modulator and nucleotide sequences, monitor amplification of preferential nucleotide sequences, absence of sequences indicates modulator
11/02/2004	US6812014 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof
11/02/2004	US6811788 Combinations and methods for treating neoplasms
11/02/2004	US6811780 Concurrent administering of cytokine antagonist and vaccine
11/02/2004	US6811779 Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
11/02/2004	US6811769 Oral composition, method of making the oral composition and oral hygiene method in japanese and chinese herbal remedy
11/02/2004	US6811768 Use of inhaled NO as anti-inflammatory agent
11/02/2004	US6811767 Liquid droplet aerosols of nanoparticulate drugs
11/02/2004	CA2364251C Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
11/02/2004	CA2338704C Oral liquid mucoadhesive compositions
11/02/2004	CA2074039C Antihypertensive combination
10/2004
10/28/2004	WO2004092731A1 Element having bioactive substance fixed thereto
10/28/2004	WO2004092215A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
10/28/2004	WO2004092122A2 Preparation and purification of synthetic capsaicin
10/28/2004	WO2004092115A2 Hydroxamates as therapeutic agents
10/28/2004	WO2004091665A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
10/28/2004	WO2004091634A1 Composition and uses of galectin antagonists
10/28/2004	WO2004091632A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor
10/28/2004	WO2004091629A1 Methods and devices for epithelial protection during photodynamic therapy
10/28/2004	WO2004091626A1 Bone growth stimulation with no/statin and other no modulating combinations
10/28/2004	WO2004091624A1 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
10/28/2004	WO2004091623A1 Pharmaceutical formulations containing methylnaltrexone
10/28/2004	WO2004091622A1 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
10/28/2004	WO2004091621A1 Alternating treatment of cancer with topoisomerase i and topoisomerase ii inhibitors
10/28/2004	WO2004091617A1 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)- (2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety
10/28/2004	WO2004091616A1 Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
10/28/2004	WO2004091615A1 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide for treatment of depression/anxiety
10/28/2004	WO2004091609A2 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
10/28/2004	WO2004091596A2 Combination therapies for chronic obstructive pulmonary disease (copd)
10/28/2004	WO2004091595A1 Use of alkyl resorcinols in the treatment of acne
10/28/2004	WO2004091593A2 Methods for the treatment of pain comprising opioid antagonists
10/28/2004	WO2004091592A2 Methods and compositions to treat myocardial conditions
10/28/2004	WO2004091573A1 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
10/28/2004	WO2004091546A2 Central nervous system stimulant and opioid antagonist combinations
10/28/2004	WO2004091531A2 Methods and devices for epithelial protection during photodynamic therapy
10/28/2004	WO2004091519A2 Methods of preventing or treating respiratory conditions
10/28/2004	WO2004091505A2 Bacteriophage for lysis of methylobacterium and compositions and uses thereof
10/28/2004	WO2004091500A2 Delivery of immune response modifier compounds
10/28/2004	WO2004091495A2 Compositions and methods related to production of erythropoietin
10/28/2004	WO2004091489A2 Topical blood pressure composition
10/28/2004	WO2004091476A2 Method of screening remedy for heart disease and medicinal composition for treating heart disease
10/28/2004	WO2004091317A1 Multi-vitamin and mineral supplement for pregnant women
10/28/2004	WO2004091307A2 Feed additives against diseasse infection in terrestrial and aquatic animals
10/28/2004	WO2004047838A3 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
10/28/2004	WO2004047766A3 Treatment for sma disease
10/28/2004	WO2004043481A3 Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
10/28/2004	WO2004041151A3 Neuroprotective iron chelators and pharmaceutical compositions comprising them
10/28/2004	WO2004032874A3 AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
10/28/2004	WO2004032867A3 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
10/28/2004	WO2004017915A3 Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition
10/28/2004	WO2004004648A3 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/28/2004	WO2003100005A3 Universal chimera bank
10/28/2004	WO2003095613A3 Nucleic acids, polypeptides, and methods for modulating apoptosis
10/28/2004	WO2003089573A3 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/28/2004	WO2003086298A3 Use of interleukin-19 to treat ovarian cancer
10/28/2004	WO2003030833A3 Angiopoietin-2 specific binding agents
10/28/2004	WO2003026591A3 Modification of feeding behavior
10/28/2004	WO2003022882A3 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
10/28/2004	WO2002088322A3 Cell adhesion and extracellular matrix proteins
10/28/2004	WO2001081540A3 Growth factor which acts through erb b-4 rtk
10/28/2004	US20040215284 Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
10/28/2004	US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders
10/28/2004	US20040214990 Transmembrane protein differentially expressed in cancer
10/28/2004	US20040214903 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
10/28/2004	US20040214902 Small molecule antagonists of BCL-2 family proteins
10/28/2004	US20040214889 administering to a patient suffering from bone disorder, a calcilytic compound, such as N-[(2R-Hydroxy-3-[(3-chloro-2-cyano)phenoxy-propyl]-1,1-dimethyl-2-(2-naphthyl)ethyl amine hydrochloride, in conjunction with an effective amount of an anti-resorptive agent.
10/28/2004	US20040214871 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester
10/28/2004	US20040214854 Cardiovascular compositions and methods using combinations of anti-platelet agents
10/28/2004	US20040214851 increasing gene expression by contacting with compound comprising imidazoquinoline amine, then contacting with opiod growth factor; pain/scarring reduction
10/28/2004	US20040214848 Concurrent administration of microbiocide and opiate inhibitors of transport proteins; drug screening
10/28/2004	US20040214842 comprises opioid analgesic agent (morphine, codeine, fentanyl, and/or methadone) and compound that binds to SS1 or SS2 subunit of sodium channel, such as tetrodotoxin and saxitoxin; side effect reduction
10/28/2004	US20040214839 administering prostaglandin or agonist thereof and type IV selective phosphodiesterase (PDE) inhibitor to induce tolerance to antigens
10/28/2004	US20040214831 cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction
10/28/2004	US20040214826 Method of treating sexual disturbances
10/28/2004	US20040214825 Method of treating sexual disturbances
10/28/2004	US20040214824 treating sexual disorders using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione
10/28/2004	US20040214823 Administering a fused aminoquinoline derivative such as (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij) quinoline-2(1H)-thione
10/28/2004	US20040214821 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
10/28/2004	US20040214814 Pyrazole compounds useful as protein kinase inhibitors
10/28/2004	US20040214804 cardiovascular disorders, hypertension, cardiovascular disease, renal dysfunction, liver disease, cerebrovascular disease, vascular disease, retinopathy, neuropathy, hyperglycemia, hyperinsulinemia and insulin resistance, edema, endothelial dysfunction; 20-spiroxane steroidal compounds
10/28/2004	US20040214792 Methods of treating inflammation
10/28/2004	US20040214781 Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
10/28/2004	US20040214765 Methods and means for inhibition of CDK4 activity
10/28/2004	US20040214762 administering serine protease inhibitors and optionally in combination with substance P or peptide hormones, for prophylaxis of nervous system disorders, autoimmune disorders and tissue regeneration processes, such as wound healing
10/28/2004	US20040214753 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
10/28/2004	US20040214752 Dispersible pharmaceutical compositions
10/28/2004	US20040214751 Using anticoagulants/angiogenesis inhibitors/thrombolytic agents
10/28/2004	US20040214283 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
10/28/2004	US20040214275 Von willebrand factor (vmf)-cleaving enzyme
10/28/2004	US20040214270 Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fattly liver in lipid biosynthesis
10/28/2004	US20040214264 Comprises nucleotide sequences coding dimethylarginine dimethylaminohydrolase-1 protein (DDAH1) for use in identifying modulators for treatment of diabetes and cardiovascular disorders

1 ... 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 ... 1151